Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of AGN-151586 for Glabellar Lines
NCT05248867Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2022
- Primary completion
- Mar 2023
- Modality
- Orthosteric Ligands, Bacterial Toxin Conjugates
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in glabellar lines comparing AGN-151586 with Placebo (2 arms). Primary endpoints: Percentage of Participants With a Grade 0 or 1 and a >= 2-grade Improvement From Baseline on the FWS According to Both Investigator and Subject Assessments of Glabellar Lines (GL) Severity at… at Day 7, Percentage of Participants With a >= 2-grade Improvement From Baseline on the FWS According to Participant Assessment of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 and 2 more. Started Mar 2022; status: completed.
02
Drugs
trenibotulinumtoxinE
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT05248867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05248867.